Pharsight

Movantik generic

Movantik is an opioid antagonist drug owned by Redhill. The active ingredient in Movantik is naloxegol oxalate. It was first authorized for market use on 16 September, 2014.

When will Movantik generic be available?

The last of Movantik's patents is set to expire on 02 April, 2032, at which point it could become possible for generic versions of the drug to be released. This is assuming no successful Paragraph IV patent challenge, which could potentially allow a generic to come to market earlier.

Movantik uses

Movantik is used for the treatment of opioid-induced constipation. The active ingredient, naloxegol oxalate, blocks the effects of opioid medication, an opioid type of drug, on the gut to prevent constipation.

Movantik patent expiration

Movantik has a total of 6 drug patents, out of which 2 have already expired. The remaining patents will expire between 2024 and 2032. Notably, US9012469, with the title 'Crystalline naloxol-peg conjugate', is the last expected to expire. Movantik generic could be available after this date. Below are the details of the patent:

EPO Oppostions filed on Movantik

Litigations filed on Movantik

Movantik dosage

Want to ask something?